Evaluation of Galectin-3 and CD19 in Helicobacter pylori patients infected with stomach cancer

Twenty nine patients infected with H. pylori and 20 infected with H. pylori and stomach cancer as well as 30 healthy individuals as control was included in this study. Cluster of Differentiation 19 (CD19) and Galectin-3 were measurement in serum of all individuals using Enzyme linked immune sorbent assay technique. The results indicated that the serum concentration of CD19 and Galactin-3 in H. pylori-patients and stomach cancer patients has been significantly increased (P-value ≤ 0.0001) as compared with control. Also, a significant increase has been detected in CD19 (P-value = 0.0035) and Galectin-3 (P-value = 0.0022) in stomach cancer patients infected with H. pylori as compared with H. pylori-patients. Conclusion: B-cell and Galectin-3 have an important synergism role in H. pylori-patients infected with stomach cancer and the high level of Galectin-3 is a good early indicator in stomach cancer in H. pylori-patients.